Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
These products are for use and handling only by persons with the knowledge and equipment to safely handle these materials
It has passed phase 1 and 2 clinical trials and is currently in phase 3 trials, with an expected launch in 2026 or 2027 if approved
GSH inhibitors such as buthionine sulfoximine (BSO) were found to improve chemosensitivity in cancer cells
Exact pricing confirmed after dermatologist skin analysis, as sessions vary based on pigmentation type, depth, skin type and individual diagnosis
Supports cell signaling and DNA repair
CTN decreased GPX4 activity and ferroportin levels and increased iron load, which induced iron-dependent lipid peroxidation
US$ 23.09
US$ 27.81
US$ 29.01
US$ 28.82
US$ 23.27
